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Conclusion: The BMD in the region of total hip, femoral neck, ultra-distal radius, 
and total body in patients with decreased muscle mass was significantly lower 
than in patients without low lean mass.
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Background: Juvenile idiopathic arthritis (JIA), one of the most common chronic 
diseases in children, can be classified in seven different categories according to 
its onset presentation. Concerns about pregnancy outcomes play a secondary 
role in disease approach. However, recent data showed an increased risk of pre-
term birth in women with JIA instead the small patient samples analysed.
Objectives: In this review, our aim is to describe the current available knowledge 
on JIA adverse, maternal and fetal, outcomes.
Methods: A systematic literature review was conducted since January of 2000 
until December 2020, by searching the PubMed and Embase bibliographic 
databases. The search was limited to articles in English language, presenting 
a comparator group (healthy individuals or patients without known auto-immune 
rheumatic diseases) and at least one clinical outcome of interest. Two independ-
ent reviewers screened the titles and abstracts followed by a full-text review to 
assess papers regarding their eligibility.
Results: Ten observational studies out of 1560 references, fulfilled the inclu-
sion criteria, of which, 9 were retrospective and 1 prospective. A total of 6.214 
women with JIA (with 6.811 pregnancies) and 18.659.513 healthy controls (with 
21.339.194 pregnancies) were included in this review.
Concerning maternal outcomes, delivery by caesarian section (CS) was more 
frequent among JIA women (in 4 out of 6 studies). Pre-eclampsia was referred 
in 3 out of 6 studies and a higher risk of vaginal bleeding and placenta previa in 
one additional study. No study found an increased risk for gestational diabetes or 
hypertension in pregnant women with JIA.
Regarding fetal outcomes, 8 studies revealed significantly increased of pre-term 
birth (only in first births in one study) but one study didn’t show any increased 
risk. Two studies showed a higher risk of small gestational age (SGA) and in 
another 2, increased risk for low birth weight (LBW). No evidence of increased 
risk of major congenital malformations.
Conclusion: This systematic review suggests an increased risk for pre-eclamp-
sia, preterm birth, delivery by CS, SGA and LBW, among pregnant women with 
JIA. Conclusions should be carefully interpreted, giving the heterogeneity of 
studied populations regarding demography, disease type, disease activity, and 
prescribed medication.
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Background: Uveitis is the most common extra-articular manifestation of juve-
nile idiopathic arthritis (JIA). Usually uveitis developed during first two years 
after arthritis occurred [1]. In the previous studies was shown the shorter time 
interval between arthritis and uveitis the severe uveitis course was observed 
[2]. Information about course of uveitis developed before arthritis is scarce.
Objectives: We aimed to evaluate the clinical features and therapy of JIA-asso-
ciated uveitis, which developed before and after joint manifestation.
Methods:  In the retrospective study 191 pediatric autoimmune uveitis included. 
The onset age ranged from 1 to 17 years. We evaluated differences in clinical, 
laboratorial and treatment differences between groups, i) where uveitis devel-
oped before (n=58) and ii) after (n=133) arthritis. Chronic autoimmune uveitis 
without joint manifestations was excluded.
Results:  Uveitits before arthritis developed in 58 (30.4%) cases. Patients whom 
uveitis developed before arthritis had were elder and characterized equal gen-
der involvement, rare ANA positivity, and rare use of immunosupression, e.g. 
corticosteroids, biologics and methotrexate, due to treatment by ophthalmologist 
predominantly. Patients developed uveitis before arthritis received biologics ear-
lier due to severity of uveitis (LogRank test, p=0.016, HR=1.97 (95%CI: 1.3; 3.1, 
p=0.004). Data are in the Table 1 and Figure 1.
Conclusion: Patients with JIA associated uveitis with initial ocular presentation 
demonstrated more severe course and delayed diagnostics and treatment due to lack 
of contacts with pediatric rheumatologist. Cooperation between ophthalmologist and 
pediatric rheumatologist is strictly required in all cases with chronic anterior uveitis.
Table 1.
Parameter Uveitis before arthritis 
(n=58)
Uveitis after arthritis 
(n=133)
p
Sex, female 32 (55,2) 97 (72,9) 0.016
Onset age, years 6.7 (4.6; 10.2) 3.2 (2; 6.1) 0.000001
JIA category
Oligoarthritis 41 (70.7) 84 (63.6) 0.174
Polyarthritis 9 (15.5) 36 (27.3)  
Enthesytis-related arthritis 8 (13.8) 12 (9.1)  
Type of uveitis
Anterior 44 (75.9) 111 (84.1) 0.315
Peripheral 3 (5.2) 2 (1.5)  
Posterior 3 (5.2) 3 (2.3)  
Panuveitis 8 (13.8) 16 (12.1)  
Unilateral uveitis, n (%) 19 (32.8) 48 (36.1) 0.632
ANA posititivity, n (%) 25/54 (46.3) 72/110 (65.5) 0.019
HLA B27 positivity, n (%) 8/35 (22.9) 13/62 (21.0) 0.828
Methotrexate, n (%) 3 (5.2) 57/132 (43.2) 0.0000001
Systemic corticosteroids, n (%) 3 (5.2) 44/131 (33.6) 0.00003
Biologic, n (%) 26 (44.8) 88 (66.2) 0.006
ESR, mm/h 19.0 (4.0; 25.0) 23 (15.0; 32.0) 0.095
CRP, mg/l 97.0 (0.1; 107.5) 8.1 (0.9; 57.4) 0.493
Time between arthritis and uveitis, 
years
2.7 (0.9; 4.3) 4.0 (2.0; 7.1) 0.016
Time before biologic, years 2.5 (0.9; 3.5) 1.3 (0.5; 5.0) 0.462
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